Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 5/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.59 |
| ▸ | MAPT | P10636 | 8/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.57 |
| ▸ | RAB9A | P51151 | 8/20 | 0.57 |
| ▸ | NPC1 | O15118 | 7/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.57 |
| ▸ | HPGD | P15428 | 7/20 | 0.57 |
| ▸ | TP53 | P04637 | 5/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.57 |
| ▸ | CASP1 | P29466 | 3/20 | 0.57 |
| ▸ | CASP7 | P55210 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALPL | P05186 | 1/20 | 0.54 |
| ▸ | ALPI | P09923 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16826561 | 0.99 | GLA (0.60) | GLAKDM4EMAPTMEN1KMT2A | |
| SCHEMBL12583468 | 0.78 | SLC16A3 (0.57) | GLAKDM4EMAPTMEN1KMT2A | |
| SCHEMBL2930650 | 0.78 | CYP19A1 (0.56) | KDM4EMAPTMAOBALDH1A1RAB9A | |
| SCHEMBL16119702 | 0.78 | RXFP1 (0.44) | GLAKDM4EMAPTMEN1KMT2A | |
| SCHEMBL29517170 | 0.77 | RAB9A (0.78) | GLAKDM4EMAPTPOLBMAOB | |
| SCHEMBL2501612 | 0.76 | CYP19A1 (0.70) | KDM4EMAPTMEN1KMT2APOLB | |
| SCHEMBL22058647 | 0.75 | MAPT (0.50) | GLAKDM4EMAPTMEN1KMT2A | |
| SCHEMBL29427468 | 0.75 | MIF (0.76) | GLAKDM4EMAPTMEN1KMT2A | |
| SCHEMBL9080679 | 0.75 | MAOB (0.60) | GLAKDM4EMAPTMEN1KMT2A | |
| SCHEMBL19348480 | 0.75 | MAOB (0.60) | GLAKDM4EMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015095449-A1 | METHODS FOR MODULATING THE AMOUNT RNA TRANSCRIPTS | PTC THERAPEUTICS, INC. (US) | 2015-06-25 | — | — | WO | claimed |
| EP-2797592-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2014-11-05 | — | — | EP | claimed |
| WO-2013101974-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | claimed |
| CN-115873003-A | Polycyclic aromatic compound, material for organic device, organic electroluminescent element, display device, and lighting device | 爱思开新材料捷恩智株式会社 | 2023-03-31 | — | — | CN | disclosed |
| US-20180072753-A1 | NOVEL ORGANIC HETEROCYCLIC COMPOUND AND LIGHT-EMITTING DEVICE COMPRISING SAME | SFC CO., LTD. (KR) | 2018-03-15 | — | — | US | disclosed |
| US-20180072753-A1 | NOVEL ORGANIC HETEROCYCLIC COMPOUND AND LIGHT-EMITTING DEVICE COMPRISING SAME | SFC CO., LTD. (KR) | 2018-03-15 | — | — | US | disclosed |
| CN-107531641-A | Oxazoline ring-containing compound, material for electron transport/injection layer containing the same, and organic electroluminescent element using the same | 捷恩智株式会社 | 2018-01-02 | — | — | CN | disclosed |
| WO-2015095449-A1 | METHODS FOR MODULATING THE AMOUNT RNA TRANSCRIPTS | PTC THERAPEUTICS, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| EP-2797592-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013101974-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| WO-2008095292-A1 | [1,2,3] TRIAZOLYL SUBSTITUTED QUINOLINES AND COUMARINS AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA LTD. (CA) | 2008-08-14 | — | — | WO | disclosed |
| US-20070032518-A1 | Compounds and methods of use | AMGEN INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20060122387-A1 | Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells | CTI EUROPE S.R.L. | 2006-06-08 | — | — | US | disclosed |
| EP-1478645-A2 | QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS | Amgen Inc. (US) | 2004-11-24 | — | — | EP | disclosed |
| US-6822097-B1 | THIAZOLE-SUBSTITUTED QUINOLINE DERIVATIVES; ANTICARCINOGENIC AGENTS, ANTISTROKE AGENTS; APOPTOSIS AND CELL PROLIFERATION TREATMENT; NERVOUS SYSTEM DISORDERS | AMGEN, INC. | 2004-11-23 | — | — | US | disclosed |
| WO-2003105842-A1 | DERIVATIVES OF CHROMEN-2-ONE AS INHIBITORS OF VEGF PRODUCTION IN MAMMALIAN CELLS | NOVUSPHARMA S.P.A. (IT) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003066630-A2 | QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS | AMGEN INC. (US) | 2003-08-14 | — | — | WO | disclosed |
| US-4404389-A | FOR DYEING PLASTICS AND SYNTHETIC FIBERS | BASF AKTIENGESELLSCHAFT (DE) | 1983-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072753-A1 | NOVEL ORGANIC HETEROCYCLIC COMPOUND AND LIGHT-EMITTING DEVICE COMPRISING SAME | OR10J3, CRY1, NR2E3 | GLA 1132/4885KDM4E 1697/4885MAPT 3200/4885 |
| US-20070032518-A1 | Compounds and methods of use | BAX, BAD, CASP3 | GLA 427/4885KDM4E 2614/4885MAPT 1974/4885 |
| US-20060122387-A1 | Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells | KDR, FLT1, VEGFA | GLA 1064/4885KDM4E 2398/4885MAPT 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.